Protecting Cancer Patients Against COVID-19: Beyond Vaccines, One Year from Vaccine Approvals
Chair’s welcome
It is with great pleasure that I invite you to participate in the third webinar of a new ESMO short series: Protecting Cancer Patients against COVID-19, which will focus on new therapeutic strategies beyond vaccines to prevent morbidity and mortality from COVID-19 in patients with cancer.
This webinar is developed with the aim to provide an overview of how to protect patients with cancer from viral pathogens. It will highlight novel anti-SARS-CoV-2 monoclonal antibodies and oral SARS-CoV-2 antiretrovirals to prevent COVID-19 related morbidity and mortality with an emphasis on their role in patients with cancer.
We will begin with a lecture on lessons learnt before COVID-19 pandemic on protecting patients with cancer from viral pathogens. This will be followed by an elaboration on prevention of COVID-19 related morbidity and mortality by administration of novel monoclonal antibodies and their impact on patients with cancer. Finally, we will evaluate the prevention of COVID-19 related morbidity and mortality by administration of novel oral, specific antiretroviral drugs with an emphasis on how to position their administration in patients with cancer.
The programme is designed to provide an overview of the current evidence, offer expert opinion exchange and provide some important considerations with regard to new specific therapeutics one year from first vaccine approvals. I strongly encourage and invite you to register and join us all in this new ESMO activity.
Dr. Christina Ruhlmann
Department of Oncology, Odense University Hospital
Odense, Denmark
Speakers
Programme
Time |
Title |
Speaker |
|---|---|---|
5 min |
Welcome and Introduction |
Christina Ruhlmann |
15 min |
Protecting patients with cancer from viral pathogens, beyond vaccines: lessons learnt in the pre-COVID era |
Nicola Giesen |
20 min |
Beyond vaccines: can monoclonal antibodies prevent COVID-related morbidity/mortality and how do we position patients with cancer? |
Marek Trněný |
15 min |
Beyond vaccines: can oral SARS-CoV-2 antiretrovirals prevent COVID-related morbidity/mortality and how do we position patients with cancer? |
Brigitte Autran |
15 min |
LIVE Q&A |
All |
A certificate of attendance and 1 ESMO MORA category point will be awarded for live attendance to this event.
Learning objectives:
- To provide an overview on how to protect patients with cancer from viral pathogens
- To highlight therapeutic interventions beyond vaccines, such as new anti-SARS-CoV-2 monoclonal antibodies for the prevention of severe morbidity and mortality in immunosuppressed or high-risk patients
- To highlight therapeutic interventions beyond vaccines, such as new SARS-CoV-2 antiretrovirals for the prevention of severe morbidity and mortality in immunosuppressed or high-risk patients
Supported by
